CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2022 | April 13, 2022
Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022
Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022 Seattle, WA — (April 13, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the developmen ...